Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
SANGAMO THERAPEUTICS, INC (SGMO)
Standardized SEC financial data for SANGAMO THERAPEUTICS, INC — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001001233 · OTC · Biological Products, (No Diagnostic Substances).
Operating margin
-306.5%
Net margin
-310.8%
Revenue growth (YoY)
-31.6%
Return on equity
861.6%
Free cash flow
-$97.3M
Current ratio
0.84×
EPS (diluted)
$-0.44
Ratios for fiscal year 2025, standardized from SEC filings.